Management of Bone Disease and Kidney Failure in Multiple Myeloma
90,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

This pocket guide provides a concise yet comprehensive overview of the two most prominent clinical features of multiple myeloma (MM), bone disease and renal failure. The first half of the text reviews critical aspects of bone disease in MM, including pathophysiology, the use of imaging modalities and drugs in treatment, and the role of orthopedic surgery. The latter half of the book reviews major components of kidney disease in MM, from pathophysiology to treatment.
Written by experts in the field, Management of Bone Disease and Kidney Failure in Multiple Myeloma: A Pocket Guide is a…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This pocket guide provides a concise yet comprehensive overview of the two most prominent clinical features of multiple myeloma (MM), bone disease and renal failure. The first half of the text reviews critical aspects of bone disease in MM, including pathophysiology, the use of imaging modalities and drugs in treatment, and the role of orthopedic surgery. The latter half of the book reviews major components of kidney disease in MM, from pathophysiology to treatment.

Written by experts in the field, Management of Bone Disease and Kidney Failure in Multiple Myeloma: A Pocket Guide is a valuable resource for clinicians and practitioners who manage patients afflicted with multiple myeloma.
Autorenporträt
Elena Zamagni, MD, PhD University of Bologna Department of Experimental, Diagnostic and Specialty Medicine Bologna, Emilia-Romagna Italy Elena Zamagni is Assistant Professor of Hematology at the University of Bologna, Italy. She received her medical degree from the University of Bologna, where she also served her residency in hematology. She obtained her PhD in Clinical Hematology at the University of Bologna in May 2005. Her research interests include areas related to multiple myeloma, in particular the role of high dose therapy with stem cell support, prognostic factors, and imaging techniques. She has published over 90 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She has contributed to the educational session of the Italian Society of Haematology. She is an active member of the board of the GIMEMA myeloma working party and she hasserved as the scientific secretary and as the principal investigator in several national randomized trials in multiple myeloma. She is also a member of the Italian Society of Haematology and of the International Myeloma Working Group. She has served on the EHA's Scientific Program Committee since 2017.